The safety and tolerability of AZD4547 (AstraZeneca, London, UK) in FGFR1 and/or FGFR2 gene amplified solid tumors and FGFR1 gene amplified squamous cell cancer is being studied in an ongoing study. This evidence concerns the gene FGFR1 and squamous cell carcinoma.